Hcw biologics reports fourth quarter and fiscal year 2024 business highlights and financial results

Miramar, fla., march 28, 2025 (globe newswire) -- hcw biologics inc. (the “company” or “hcw biologics”) (nasdaq: hcwb), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended december 31, 2024.
HCWB Ratings Summary
HCWB Quant Ranking